Eiger BioPharmaceuticals, Inc.
Case Number:
8:24-bk-80040
Court:
Nature of Suit:
Firms
- Bradley Arant
- Buchalter APC
- Butler Snow LLP
- Condon Tobin
- Covington & Burling
- Goodwin Procter
- Gray Reed
- Greenberg Traurig
- Kane Russell
- Kramer Levin
- McKool Smith
- Meland Budwick
- Morrison Foerster
- Munsch Hardt
- Neligan LLP
- Parsons Behle
- Paul Hastings
- Pillsbury Winthrop
- Polsinelli PC
- Porzio Bromberg
- Ropes & Gray
- Sidley Austin
- Spencer Fane
- Stromberg Stock
- Tucker Arensberg
- Vartabedian Hester
- Weil Gotshal
- Winstead PC
Companies
- Alvarez & Marsal Holdings LLC
- Amylyx Pharmaceuticals Inc.
- Deloitte Touche Tohmatsu Ltd.
- Dundon Advisers LLC
- Eiger BioPharmaceuticals
- Eton Pharmaceuticals
- Fujifilm
- Iqvia Holdings Inc.
- Merck & Co. Inc.
- Oracle Corp.
- Oxford Finance LLC
- Thermo Fisher Scientific Inc.
- Verita Global LLC
Government Agencies
Sectors & Industries:
-
April 15, 2024
US Trustee Wants Biotech Eiger's Ch. 11 Booted From Texas
The U.S. Trustee's Office has asked a Texas bankruptcy judge to remove the Chapter 11 case of Eiger BioPharmaceuticals Inc. from the Lone Star State, saying the company cannot justify bringing it there.
-
April 03, 2024
Biotech Eiger Can Take Sentynl's Improved Drug Bid In Ch. 11
Eiger BioPharmaceuticals Inc. received approval Wednesday to select a $30 million base offer for its Zokinvy drug and use cash collateral after a Texas bankruptcy judge dismissed objections to the relief, allowing the company to move ahead with a planned auction for its rare-disease treatments.
-
April 01, 2024
Eiger BioPharmaceuticals Hits Ch. 11 With $53.1M Debt
Eiger BioPharmaceuticals Inc. filed for Chapter 11 protection in Texas bankruptcy court Monday with $53.1 million of debt and plans to sell its assets during the case.
- ← Previous
- 1
- 2
- Next →